1. |
|
|
2. |
|
|
3. |
|
|
4. |
- Ademuyiwa, Adesoji O., et al.
(författare)
-
Determinants of morbidity and mortality following emergency abdominal surgery in children in low-income and middle-income countries
- 2016
-
Ingår i: BMJ Global Health. - : BMJ Publishing Group Ltd. - 2059-7908. ; 1:4
-
Tidskriftsartikel (refereegranskat)abstract
- Background: Child health is a key priority on the global health agenda, yet the provision of essential and emergency surgery in children is patchy in resource-poor regions. This study was aimed to determine the mortality risk for emergency abdominal paediatric surgery in low-income countries globally.Methods: Multicentre, international, prospective, cohort study. Self-selected surgical units performing emergency abdominal surgery submitted prespecified data for consecutive children aged <16 years during a 2-week period between July and December 2014. The United Nation's Human Development Index (HDI) was used to stratify countries. The main outcome measure was 30-day postoperative mortality, analysed by multilevel logistic regression.Results: This study included 1409 patients from 253 centres in 43 countries; 282 children were under 2 years of age. Among them, 265 (18.8%) were from low-HDI, 450 (31.9%) from middle-HDI and 694 (49.3%) from high-HDI countries. The most common operations performed were appendectomy, small bowel resection, pyloromyotomy and correction of intussusception. After adjustment for patient and hospital risk factors, child mortality at 30 days was significantly higher in low-HDI (adjusted OR 7.14 (95% CI 2.52 to 20.23), p<0.001) and middle-HDI (4.42 (1.44 to 13.56), p=0.009) countries compared with high-HDI countries, translating to 40 excess deaths per 1000 procedures performed.Conclusions: Adjusted mortality in children following emergency abdominal surgery may be as high as 7 times greater in low-HDI and middle-HDI countries compared with high-HDI countries. Effective provision of emergency essential surgery should be a key priority for global child health agendas.
|
|
5. |
- Kaiser, Brooks A., et al.
(författare)
-
Spatial issues in Arctic marine resource governance workshop summary and comment
- 2015
-
Ingår i: Marine Policy. - : Elsevier BV. - 0308-597X .- 1872-9460. ; 58, s. 1-5
-
Tidskriftsartikel (refereegranskat)abstract
- The rapidly changing Arctic marine ecosystems face new challenges and opportunities that are increasing and shifting governance needs in the region. A group of economists, ecologists, biologists, political scientists and resource managers met in Stockholm, SE, Sept 4-6, 2014 to discuss the governance of Arctic marine resources in a spatial context. We report on the findings here.
|
|
6. |
- Thorarinsdottir, Elin H., et al.
(författare)
-
Definition of excessive daytime sleepiness in the general population : Feeling sleepy relates better to sleep-related symptoms and quality of life than the Epworth Sleepiness Scale score. Results from an epidemiological study
- 2019
-
Ingår i: Journal of Sleep Research. - : WILEY. - 0962-1105 .- 1365-2869. ; 28:6
-
Tidskriftsartikel (refereegranskat)abstract
- Many different subjective tools are being used to measure excessive daytime sleepiness (EDS) but the most widely used is the Epworth Sleepiness Scale (ESS). However, it is unclear if using the ESS is adequate on its own when assessing EDS. The aim of this study was to estimate the characteristics and prevalence of EDS using the ESS and the Basic Nordic Sleep Questionnaire (BNSQ) in general population samples. Participants aged 40 years and older answered questions about sleepiness, health, sleep-related symptoms and quality of life. Two groups were defined as suffering from EDS: those who scored >10 on the ESS (with increased risk of dozing off) and those reporting feeling sleepy during the day >= 3 times per week on the BNSQ. In total, 1,338 subjects (53% male, 74.1% response rate) participated, 13.1% reported an increased risk of dozing off, 23.2% reported feeling sleepy and 6.4% reported both. The prevalence of restless leg syndrome, nocturnal gastroesophageal reflux, difficulties initiating and maintaining sleep and nocturnal sweating was higher among subjects reporting feeling sleepy compared to non-sleepy subjects. Also, subjects reporting feeling sleepy had poorer quality of life and reported more often feeling unrested during the day than non-sleepy subjects. However, subjects reporting increased risk of dozing off (ESS > 10) without feeling sleepy had a similar symptom profile as the non-sleepy subjects. Therefore, reporting only risk of dozing off without feeling sleepy may not reflect problematic sleepiness and more instruments in addition to ESS are needed when evaluating daytime sleepiness.
|
|
7. |
- Thorarinsdottir, Elin H., et al.
(författare)
-
Serum ferritin and obstructive sleep apnea-epidemiological study
- 2018
-
Ingår i: Sleep and Breathing. - : SPRINGER HEIDELBERG. - 1520-9512 .- 1522-1709. ; 22:3, s. 663-672
-
Tidskriftsartikel (refereegranskat)abstract
- PurposeFerritin is an intracellular iron storage protein and a marker of inflammation. Studies have shown that subjects with obstructive sleep apnea (OSA) have higher levels of circulating pro-inflammatory cytokines, but little is known about the association between ferritin and OSA. The aims of the study were to evaluate serum ferritin (S-Ferritin) levels in OSA patients compared to levels in the general population and also examine the effect of obesity level and treatment with positive airway pressure (PAP) on S-Ferritin levels.MethodsThe OSA subjects (n=796) were part of the Icelandic Sleep Apnea Cohort. The control subjects (n=637) were randomly chosen Icelanders who participated in an epidemiological study. Propensity score (PS) methodologies were employed to minimize selection bias and strengthen causal inferences when comparing non-randomized groups. S-Ferritin levels were measured and all participants answered the same detailed questionnaire about sleep and health. Only OSA patients underwent a sleep study and were re-invited for a 2-year follow-up.ResultsS-Ferritin levels were significantly higher in OSA males than controls (213.3 vs. 197.3g/L, p=0.007). However, after adjusting for confounders and using our PS methodology, no significant difference was found. S-Ferritin levels were not correlated with severity of OSA, obesity level, or clinical symptoms. Also, no significant change in S-Ferritin levels was found with 2years of PAP treatment.ConclusionsS-Ferritin levels are comparable in OSA patients and controls and do not change consistently with obesity level or PAP treatment in our sample.
|
|
8. |
- Thorarinsdottir, Katrin, et al.
(författare)
-
CD21(-/low) B cells associate with joint damage in rheumatoid arthritis patients
- 2019
-
Ingår i: Scandinavian Journal of Immunology. - : Wiley. - 0300-9475 .- 1365-3083. ; 90:2
-
Tidskriftsartikel (refereegranskat)abstract
- Depletion of B cells is beneficial in rheumatoid arthritis (RA) patients with autoantibodies to citrullinated proteins (ACPA) and/or the Fc portion of immunoglobulins (rheumatoid factor [RF]), suggesting a role for B cells in disease pathogenesis. To date, however, the identity of specifically pathogenic B cell subsets has not been discovered. One candidate population is identified by the low expression or absence of complement receptor 2 (CD21(-/low) B cells). In this study, we sought to determine whether there was any correlation between CD21(-/low) B cells and clinical outcome in patients with established RA, either ACPA(+)/RF+ (n = 27) or ACPA(-)/RF- (n = 10). Healthy donors (n = 17) were included as controls. The proportion of the CD21(-/low) CD27(-)IgD(-) memory B cell subset in peripheral blood (PB) was significantly increased in ACPA(+)/RF+ RA patients compared with healthy donors, and the frequency of this subset correlated with joint destruction (r = 0.57, P < 0.04). The levels of the chemokines CXCL-9 and CXCL-10 were higher in synovial fluid than in plasma, and PB CD21(-/low) cells expressed the receptor, CXCR3. In synovial fluid, most of the B cells were CD21(-/low), approximately 40% of that population was CD27(-)IgD(-), and a third of those expressed the pro-osteoclastogenic factor receptor activator of the nuclear factor kappa B ligand (RANKL). This subset also secreted RANKL, in addition to other factors such as IL-6, even in the absence of stimulation. We interpret these data as reason to propose the hypothesis that the CD27(-)IgD(-) subset of CD21(-/low) B cells may mediate joint destruction in patients with ACPA(+)/RF+ RA.
|
|
9. |
- Thorarinsdottir, Katrin, et al.
(författare)
-
CD21-/low B cells in human blood are memory cells
- 2016
-
Ingår i: Clinical and Experimental Immunology. - : Oxford University Press (OUP). - 0009-9104 .- 1365-2249. ; 185:2, s. 252-262
-
Tidskriftsartikel (refereegranskat)abstract
- The complement receptor 2 (CR2, CD21) is part of a complex (CD21/CD19/CD81) acting as a co-receptor to the B-cell receptor (BCR). Simultaneous triggering of the BCR and CD21 lowers the threshold for B-cell activation. Although CD21 is important, B cells that express low amounts or lack surface CD21 (CD21-/low) are increased in conditions with chronic inflammation, e.g. autoimmune diseases. However, little is known about the CD21-/low B-cell subset in peripheral blood from healthy donors. Here, we show that CD21-/low cells represent around 5% of B cells in peripheral blood from adults but are barely detectable in cord blood, after excluding transitional B cells. The CD21-/low subset can be divided into CD38-24+ and CD38-24low cells, where most of the CD38-24+ are CD27+IgM+IgD+ and the CD38-24low are switched CD27-. Expression levels of additional markers, e.g. CD95 and CD62L, are similar to those on classical memory B cells. In contrast to naïve cells, the majority of CD21-/low cells lack expression of the ABCB1 transporter. Stimulation with a combination of BCR, toll-like receptor (TLR) 7/8 and IL-2 induces proliferation and differentiation of the CD21-/low B-cells comparable to CD21+CD27+ memory B cells. The response excluding BCR agonist is not on par with that of classical memory B cells, though clearly above that of naïve B cells. This is ascribed to a weaker response by the CD38-24low subset, implying that some memory B cells require not only TLR but also BCR triggering. We conclude that the CD21-/low B cells in healthy donors are memory B cells.
|
|
10. |
- Tranberg, A, et al.
(författare)
-
Proton pump inhibitor medication is associated with colonisation of gut flora in the oropharynx
- 2018
-
Ingår i: Acta Anaesthesiologica Scandinavica. - : Wiley. - 0001-5172. ; 62:6, s. 791-800
-
Tidskriftsartikel (refereegranskat)abstract
- BACKGROUND: The normal body exists in mutualistic balance with a large range of microbiota. The primary goal of this study was to establish whether there is an imbalance in the oropharyngeal flora early after hospital or ICU admittance, and whether flora differs between control, ward and critically ill patients. The secondary goal was to explore whether there are patient characteristics that can be associated with a disturbed oropharyngeal flora.METHODS: Oropharyngeal cultures were obtained from three different study groups: (1) controls from the community, (2) ward patients and (3) critically ill patients, the two latter within 24 h after admittance.RESULTS: Cultures were obtained from 487 individuals: 77 controls, 193 ward patients and 217 critically ill patients. Abnormal pharyngeal flora was more frequent in critically ill and ward patients compared with controls (62.2% and 10.4% vs. 1.3%, P < 0.001 and P = 0.010, respectively). Colonisation of gut flora in the oropharynx was more frequent in critically ill patients compared with ward patients or controls (26.3% vs. 4.7% and 1.3%, P < 0.001 and P < 0.001, respectively). Proton pump inhibitor medication was the strongest independent factor associated with the presence of gut flora in the oropharynx in both ward and critically ill patients (P = 0.030 and P = 0.044, respectively).CONCLUSION: This study indicates that abnormal oropharyngeal flora is an early and frequent event in hospitalised patients and more so in the critically ill, compared to controls. Proton pump inhibitor medication is associated with colonisation of gut flora in the oropharynx.
|
|